MedActiv™ Monograph References Only · Distributed!exclusively!by:!!!!!...

Distributed exclusively by: Innovations 4 Health LLC “Better Living Through Science”

+ MedActiv™ Monograph References

A Medical Food for the Dietary Management of Obesity Exclusively by Innovations 4 Health

1 O'Rourke DA, Wurtman JJ, Wurtman RJ, et al. Aberrant snacking patterns and eating disorders in patients with obsessive compulsive disorder. J Clin Psychiatry. 1994 Oct;55(10):445-‐7.

2 Avena NM, Rada P, Hoebel BG (2009) Sugar and fat bingeing have notable differences in addictive-‐like behavior. J Nutr 139: 623–628. doi: 10.3945/jn.108.097584 PMID.

3 Haslam DW(1), James WP. Obesity. Lancet. 2005 Oct 1;366(9492):1197-‐209. 4 Wadden TA, Butryn ML, Byrne KJ (2004) Efficacy of lifestyle modification for long-‐term weight control. Obes Res 12 Suppl: 151S–162S. PMID.

5 Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK (2008) Will All Americans Become Over-‐ weight or Obese? Estimating the Progression and Cost of the U.S. Obesity Epidemic. Obesity 16: 2323–2330.

6 Poulain M(1), Doucet M, Major GC, Drapeau V, Sériès F, Boulet LP, Tremblay A, Maltais F.CMAJ. 2006 Apr 25;174(9):1293-‐9.

7 Manson JE, Willett WC, Stampfer MJ et al. (1995). "Body weight and mortality among women". N. Engl. J. Med. 333 (11): 677–85.

8 Bleich S, Cutler D, Murray C, Adams A (2008). "Why is the developed world obese?". Annu Rev Public Health (Research Support) 29: 273–95.

9 Gearhardt AN, Yokum S, Orr PT, Stice E, Corbin WR, et al. (2011) Neural correlates of food addiction. Archives of general psychiatry 68: 808–816.

10 Avena NM, Rada P, Hoebel BG (2009) Sugar and fat bingeing have notable differences in addictive-‐like behavior. J Nutr 139: 623–628.

11 Oswald KD, Murdaugh DL, King VL, Boggiano MM (2011) Motivation for palatable food despite consequences in an animal model of binge eating. International journal of eating disorders 44: 203–211.

12 Schulte EM, Avena NM, Gearhardt AN (2015) Which Foods May Be Addictive? The


MedActiv™ for the Dietary Management of Obesity 2

Roles of Processing, Fat Content, and Glycemic Load. PLoS ONE 10(2). e0117959 doi:10.1371/journal. pone.0117959.

13 Monteiro CA, Levy RB, Claro RM, Castro IR, Cannon G (2010) A new classification of foods based on the extent and purpose of their processing. Cad Saude Publica 26: 2039–2049.

]

14 Page, Kathleen, Fatty food pictures encourages impulse eating. Presentation at the Endocrine society 94th Annual Meeting.

15 Gearhardt AN, White MA, Potenza MN (2011) Binge eating disorder and food addiction. Current drug abuse reviews 4: 201.

16 Davis C, Curtis C, Levitan RD, Carter JC, Kaplan AS, et al. (2011) Evidence that ‘food addiction’ is a valid phenotype of obesity. Appetite 57: 711–717.

17 Gearhardt AN, Yokum S, Orr PT, Stice E, Corbin WR, et al. (2011) Neural correlates of food addiction. Archives of general psychiatry 68: 808–816.

18 Abizaid A, Liu ZW, Andrews ZB, Shanabrough M, Borok E, Els-‐ worth JD, Roth RH, Sleeman MW, Picciotto MR, Tschop MH, Gao XB, Horvath TL. Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. J Clin Invest 116: 3229 –3239, 2006.

19 Greeno CG, Wing RR. Stress-‐induced eating. Psychol Bull. 1994 May;115(3):444-‐64. 20 Lattimore P, Caswell N. Differential effects of active and passive stress on food intake in restrained and unrestrained eaters. Appetite. 2004 Apr;42(2):167-‐73.

21 Polivy J, Herman CP. Distress and eating: why do dieters overeat? Int J Eat Disord. 1999 Sep;26(2):153-‐64.

22 Polivy J, Herman CP. Distress and eating: why do dieters overeat? Int J Eat Disord. 1999 Sep;26(2):153-‐64.

23 Laitinen J, Ek E, Sovio U. Stress-‐related eating and drinking behavior and body mass index and predictors of this behavior. Prev Med. 2002 Jan;34(1):29-‐39.

24 Pecoraro N, Reyes F, Gomez F, Bhargava A, Dallman MF. Chronic stress promotes palatable feeding, which reduces signs of stress: feedforward and feedback effects of chronic stress. Endocrinology. 2004 Aug;145(8):3754-‐62.



25 TC, Epel ES. Stress, eating and the reward system. Physiol Behav. 2007;91:449-‐58. 26 Warne JP. Shaping the stress response: interplay of palatable food choices, glucocorticoids, insulin and abdominal obesity. Mol Cell Endocrinol. 2009 Mar 5;300(1-‐2):137-‐46.

27 Johnson PM, Kenny, PJ. Dopamine D2 receptors in addiction-‐like reward dysfunction and compulsive eating in obese rats. Nat Neurosci. 2010 May;13(5):635-‐41.

28 Dallman MF, Pecoraro N, Akana SF, et al. Chronic stress and obesity: a new view of "comfort food." PNAS USA. 2003;100: 11696-‐701.

29 Bjorntorp P, Rossner S, Udden J. "Consolatory eating" is not a myth. Stress-‐induced increased cortisol levels result in leptin-‐resistant obesity. Lakartidningen. 2001;98:5458-‐61.

30 Alsiö J, Olszewski PK, Levine AS, Schiöth HB. Feed-‐forward mechanisms: Addiction-‐like behavioral and molecular adaptations in overeating. Front Neuroendocrinol. Epub 2012 Jan 28.

31 Luppino FS1, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, Zitman FG., Overweight, obesity, and depression: a systematic review and meta-‐analysis of longitudinal studies. Arch Gen Psychiatry. 2010 Mar;67(3):220-‐9. doi: 10.1001/archgenpsychiatry.2010.2.

32 Roy Perlis, M.D., associate professor of psychiatry, Harvard Medical School, and director, Center for Experimental Drugs and Diagnostics, Massachusetts General Hospital, Boston; June 4, 2014, JAMA Psychiatry, online

33 Adam TC, Epel ES. Stress, eating and the reward system. Physiol Behav. 2007;91:449-‐58. 34 Bjorntorp P, Rossner S, Udden J. "Consolatory eating" is not a myth. Stress-‐induced increased cortisol levels result in leptin-‐resistant obesity. Lakartidningen. 2001;98:5458-‐61.

35 McManus, Kathy, M.S., R.D., L.D.N., Lose weight and keep it off. Harvard Special Report, Harvard Medical School. 2012

36 Douglas AJ (March 2005). "Central noradrenergic mechanisms underlying acute stress responses of the Hypothalamo–pituitary–adrenal axis: adaptations through pregnancy and lactation". Stress 8 (1): 5–18. doi:10.1080/10253890500044380. PMID 16019594.

37 Detillion CE, Craft TK, Glasper ER, Prendergast BJ, DeVries AC (September 2004).



"Social facilitation of wound healing". Psychoneuroendocrinology 29 (8): 1004–11.

38 Albert PR, Benkelfat C. The neurobiology of depression—revisiting the serotonin hypothesis. II. Genetic, epigenetic and clinical studies. Philosophical Transactions of the Royal Society B: Biological Sciences. 2013;368(1615):20120535. doi:10.1098/rstb.2012.0535.

39 H. Ettehadi, S. Mojabi, M. Ranjbaran, J. Shams, H. Sahraei, M. Hedayati and F. Asefi, "Aqueous Extract of Saffron (Crocus sativus) Increases Brain Dopamine and Glutamate Concentrations in Rats," Journal of Behavioral and Brain Science, Vol. 3 No. 3, 2013, pp. 315-‐319. doi: 10.4236/jbbs.2013.33031.

40 Shams Jamal, Hedayati Mehdi, Asefi F., European Neuropsychopharmacology (Impact Factor: 5.4). 08/2010; 20. DOI: 10.1016/S0924-‐977X(10)70491-‐0

41 Noury J, Bourges C. Enquête sur l'impact du complément alimentaire SATIEREAL chez des femmes ayant une tendance à l'hyperphagie réflexe non pathologique. Nutraveris. 2006; unpublished study.

42 Gout B, Bourges C, Paineau-‐Dubreuil S. Satiereal, a Crocus sativus L extract, reduces snacking and increases satiety in a randomized placebo-‐controlled study of mildly overweight, healthy women. Nutr Res. 2010 May;30(5):305-‐13.

43 Y okogoshi H1, Kobayashi M, Mochizuki M, Terashima T.Effect of theanine, r-‐ glutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats. Neurochem Res. 1998 May ;23(5):667-‐73.

44 Van Praag HM, Lemus C. Monoamine precursors in the treatment of psychiatric disorders. In: Wurtman RJ, Wurtman JJ, eds. Nutrition and the Brain. New York: Raven Press; 1986:89-‐139.

45 den Boer JA, Westenberg HG. Behavioral, neuroendocrine, and biochemical effects of 5-‐ hydroxytryptophan administration in panic disorder. Psychiatry Res 1990;31:267-‐278.

46 Chadwick D, Jenner P, Harris R, et al. Manipulation of brain serotonin in the treatment of myoclonus. Lancet 1975;2:434-‐435.



47 Guilleminault C, Tharp BR, Cousin D. HVA and 5HIAA CSF measurements and 5HTP trials in some patients with involuntary movements. J Neurol Sci 1973;18:435-‐441.

48 Antidepressant-‐like activity of the Gastrodia elata ethanol extract in mice. Zhou BH, Li XJ, Liu M, Wu Z, Ming Hu X. Fitoterapia. 2006 Dec; 77(7-‐8):592-‐4. Epub 2006 Sep 22.

49 Rödel W, Petrzika M. Analysis of the volatile components of saffron. J High Res Chromatogr. 1991;14:771-‐4.

50 Bhargava, Vijaya. Medicinal uses and pharmacological properties of crocus sativus, International Journal of Pharmacy and Pharmaceutical Sciences. Vol 3, Supplement 3, 2011

51 Himeno H, Sano K. Synthesis of crocin, picrocrocin and safranal by saffron stigma-‐like structures proliferated in vitro. Agric Biol Chem. 1987;51(9):2395-‐400.

52 Hosseinzadeh, Hosse,n Nassiri-‐Asl Marjan, Avicenna’s (Ibn Sina) the canon of medicine and saffron (Crocus sativus): a review. Phytother. Res. 27: 475–483 (2013) Published online 20 July 2012 in Wiley Online Library DOI: 10.1002/ptr.4784

53 Akhondzadeh Shahin, Fallah-‐Pouri Hasan, Afkhami Khosro, Jamshidi Hossein, Khalighi-‐ Cigaroudi Khaligi. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: A pilot double-‐blind randomized trial. BMC Complementary and Alternative Medicine 2004, 4:12 doi:10.1186/1472-‐6882-‐4-‐12.

54 Fluoxetine versus other types of pharmacotherapy for depression. Magni LR, Purgato M, Gastaldon C, Papola D, Furukawa TA, Cipriani A, Barbui C. Cochrane Database Syst Rev. 2013 Jul 17; 7:CD004185. Epub 2013 Jul 17.

55 Luppino FS1, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, Zitman FG Overweight, obesity, and depression: a systematic review and meta-‐analysis of longitudinal studies. Arch Gen Psychiatry. 2010 Mar ;67(3):220-‐9. doi: 10.1001/archgenpsychiatry.2010.2.

56 Yaryura-‐Tobias JA, Heller B, Spatz H, et al. Phenylalanine for endogenous depression. J Orthomol Psychiatry 1974;3:80-‐81.

57 Fischer E, Heller B, Nachon M, Spatz H. Therapy of depression by



phenylalanine. Preliminary note. Arzneimittelforschung 1975;25:132. 58 Heller B. Pharmacological and clinical effects of DL-‐phenylalanine in the treatment of depression and Parkinson’s disease. In: Mosnaim AD, Wolfe ME, eds. Modern Pharmacology-‐Toxicology, Noncatecholic Phenylethylamines, Part 1. New York: Marcel Dekker; 1978:397-‐417.

59 Ballinger AB1, Clark ML.L-‐phenylalanine releases cholecystokinin (CCK) and is associated with reduced food intake in humans: evidence for a physiological role of CCK in control of eating. Metabolism. 1994 Jun ;43(6):735-‐8.

60 Pohle-‐Krauza RJ1, Carey KH, Pelkman CL Dietary restraint and menstrual cycle phase modulated L-‐phenylalanine-‐induced satiety. Physiol Behav. 2008 Mar 18 ;93(4-‐5):851-‐61. doi: 10.1016/j.physbeh.2007.11.051. Epub 2007 Dec 5

61 Godfraind JM, Plaghi L, De Nayer J. A comparative study on the effects of D-‐phenylalanine, lysozyme and zimelidine in human lumbosacral arachno-‐epiduritis. A chronic pain state. In: Bromm B, ed. Pain Measurement in Man: Neurophysiological Correlates of Pain. New York, NY: Elsevier; 1984:501-‐511.

62 Dietary Guidelines for Americans 2005. Rockville, MD : US Dept of Health and Human Services and US Dept of Agriculture; 2005.

63 Hoeger WW1, Harris C, Long EM, Hopkins DR. Four-‐week supplementation with a natural dietary compound produces favorable changes in body composition. Adv Ther. 1998 Sep-‐Oct ;15(5):305-‐14

64 Beckmann H, Strauss MA, Ludolph E. DL-‐phenylalanine in depressed patients: an open study. J Neural Transm 1977;41:123-‐134.

65 Beckmann H, Athen D, Olteanu M, Zimmer R. DL-‐phenylalanine versus imipramine: a double-‐blind controlled study. Arch Psychiatr Nervenkr 1979;227:49-‐58. Heller B. Pharmacological and clinical effects of D-‐phenylalanine in depression and Parkinson’s disease. In: Mosnaim AD, Wolf ME, eds. Noncatecholic Phenylethylamines. Part 1. New York, NY: Marcel Dekker; 1978:397-‐417.

66 Heller B. Pharmacological and clinical effects of DL-‐phenylalanine in the treatment of depression and Parkinson’s disease. In: Mosnaim AD, Wolfe ME, eds. Modern Pharmacology-‐Toxicology, Noncatecholic Phenylethylamines, Part 1. New York: Marcel Dekker; 1978:397-‐417.

67 Ehrenpreis S, Bagalot RC, Greenberg J, et al. Analgesic and other pharmacological



properties of D-‐ phenylalanine. In: Ehrenpreis S, Sicuteri F, eds. Degradation of Endogenous Opioids: Its Relevance in Human Pathology and Therapy. New York, NY: Raven Press; 1983:171-‐ 187.

68 Ehrenpreis S, Bagalot RC, Greenberg J, et al. Analgesic and other pharmacological properties of D-‐phenylalanine. In: Ehrenpreis S, Sicuteri F, eds. Degradation of Endogenous Opioids: Its Relevance in Human Pathology and Therapy. New York, NY: Raven Press; 1983:171-‐187.

69 Young SN (2007). "How to increase serotonin in the human brain without drugs". Rev. Psychiatr. Neurosci. 32 (6): 394–99. PMC 2077351. PMID 18043762.

70 Portas CM1, Bjorvatn B, Ursin R. Serotonin and the sleep/wake cycle: special emphasis on microdialysis studies. Prog Neurobiol. 2000 Jan ;60(1):13-‐35.

71 Pohle-‐Krauza RJ, Carey KH, Pelkman CL. Physiol Behav. 2008 Mar 18;93(4-‐5):851-‐61. doi: 10.1016/j.physbeh.2007.11.051. Epub 2007 Dec 5. PMID: 18206190

72 Wurtman RJ1, Wurtman JJ. Brain serotonin, carbohydrate-‐craving, obesity and depression. Obes Res. 1995 Nov ;3 Suppl 4:477S-‐480S.

73 Monograph 5-‐Hydroxytryptophan Thorne Research Page 226Alternative Medicine Review Volume 3, Number 3 1998.

74 Cangiano C, Ceci F, Cascino A, et al. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-‐hydroxytryptophan. Am J Clin Nutr 1992;56:863-‐867.

75 van Praag HM, Lemus C. Monoamine precursors in the treatment of psychiatric disorders. In: Wurtman RJ, Wurtman JJ, eds. Nutrition and the Brain. New York: Raven Press; 1986:89-‐ 139.

76 den Boer JA, Westenberg HG. Behavioral, neuroendocrine, and biochemical effects of 5-‐ hydroxytryptophan adminis-‐ tration in panic disorder. Psychiatry Res 1990;31:267-‐278.

77 Chadwick D, Jenner P, Harris R, et al. Manipulation of brain serotonin in the treatment of myoclonus. Lancet 1975;2:434-‐435.



78 Guilleminault C, Tharp BR, Cousin D. HVA and 5HIAA CSF measurements and 5HTP trials in some patients with involuntary movements. J Neurol Sci 1973;18:435-‐441.

79 Poldinger W, Calanchini B, Schwarz W. A functional-‐dimensional approach to depression: serotonin deficiency as a target syndrome in a comparison of 5-‐hydroxytryptophan and fluvoxamine. Psychopathology 1991;24:53-‐81.

79 Soulairac A, Lambinet H. Effect of 5-‐hydroxytryptophan, a serotonin precursor, on sleep disorders. Ann Med Psychol 1977;1:792-‐798.

81 Guilleminault C, Cathala JP, Castaigne P. Effects of 5-‐hydroxytryptophan on sleep of a patient with a brain-‐stem lesion. Electroencephalogr Clin Neurophysiol 1973;34:177-‐184.

82 Wyatt RJ, Zarcone V, Engelman K, et al. Effects of 5-‐hydroxytryptophan on the sleep of normal human subjects. Electroencephalogr Clin Neurophysiol 1971;30:505-‐509.

83 Taheri S. The link between short sleep duration and obesity: We should recommend more sleep to prevent obesity. Arch Dis Child 2006;91:881–884.

84 Ito K, Nagato Y, Aoi N, et al. Effects of L-‐ theanine on the release of alpha-‐brain waves in human volunteers. Nippon Nogeikagaku Kaishi 1998;72:153-‐157.

85 Yokogoshi H, Kobayashi M, Mochizuki M, Terashima T. Effect of theanine, r-‐glutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats. Neurochem Res 1998;23:667-‐673.

86 Haskell CF1, Kennedy DO, Milne AL, Wesnes KA, Scholey AB.The effects of L-‐theanine, caffeine and their combination on cognition and mood. Biol Psychol. 2008 Feb ;77(2):113-‐ 22. Epub 2007 Sep 26.

87 Owen, Gail N.; Parnell, Holly; De Bruin, Eveline A.; Rycroft, Jane A. (2008). "The combined effects of L-‐theanine and caffeine on cognitive performance and mood". Nutritional Neuroscience 11 (4): 193–8. doi:10.1179/147683008X301513. PMID 18681988.

88 Kakuda T, Nozawa A, Unno T, et al. Inhibiting effects of theanine on caffeine stimulation evaluated by EEG in the rat. Biosci Biotechnol Biochem 2000;64:287-‐293.

89 Higashiyama A, et al. Journal of Functional Foods Effects of L-‐theanine on attention and reaction time response. 2011:3(3):171-‐8.



90 Juneja, Lekh Raj Chu,Djong-‐Chi L-‐theanine-‐a unique amino acid of green tea and its relaxation effect in humans Trends in Food Science & Technology 10 (1999) 199-‐204

91 Sugiyama T, Sadzuka Y. Combination of theanine with doxorubicin inhibits hepatic metastasis of M5076 ovarian sarcoma. Clin Cancer Res 1999;5:413-‐416.

92 Sadzuka Y, Sugiyama T, Miyagishima A, et al. The effects of theanine, as a novel biochemical modulator, on the antitumor activity of adriamycin. Cancer Lett 1996;105:203-‐ 209.

93 Dulloo AG, Seydoux J, Girardier L, Chantre P, Vandermander J. Green tea and thermogenesis: interactions between catechin-‐polyphenols, caffeine and sympathetic activity. Int J Obes Relat Metab Disord. 2000 Feb;24(2):252-‐8.

94 Gibson CJ, Wurtman RJ. Physiological control of brain catechol synthesis by brain tyrosine concentration. Biochem Pharmacol 1977;26:1137-‐1142.

95 Wurtman RJ, Larin F, Mostafapour S, Fernstrom JD. Brain catechol synthesis: control by brain tyrosine concentration. Science 1974;185:183-‐184.

96 Banderet LE, Leiberman HR. Treatment with tyrosine, a neurotransmitter precursor, reduces environmental stress in humans. Brain Res Bull 1989;22:759-‐762.

97 Brown D, Gaby AR, Reichert R. Natural remedies for depression. Nutr Sci News 1999;February.

98 Deijen JB, Wientjes CJ, Vullinghs HF, Cloin PA, Langefeld JJ (1999). "Tyrosine improves cognitive performance and reduces blood pressure in cadets after one week of a combat training course". Brain Res. Bull. 48 (2): 203–9. doi:10.1016/S0361-‐9230(98)00163-‐4.

99 Neri DF, Wiegmann D, Stanny RR, et al. The effects of tyrosine on cognitive performance during extended wakefulness. Aviat Space Environ Med 1995;66:313-‐319.

100 Gelenberg AJ, Wojcik JD, Growdon JH, et al. Tyrosine for the treatment of depression. Am J Psychiatry 1980;137:622-‐623.

101 Gelenberg A, Wojcik JD, Gibson CJ, Wurtman RJ. Tyrosine for depression. J Psychiatr Res 1982-‐1983;17:175-‐180.



102 Petkov VD, Yonkov D, Mosharoff A, et al. Effects of alcohol aqueous extract from Rhodiola rosea L. roots on learning and memory. Acta Physiol Pharmacol Bulg 1986;12:3-‐16.

103 Seifulla RD. (1999). Sport Pharmacology. Manual. Sport Pharma Publishing, Moscow. 104p 104 Hung SK, Perry R, Ernst E. The effectiveness and efficacy of Rhodiola rosea L.: a systematic review of randomized clinical trials. Phytomedicine. 2011 Feb 15;18(4):235-‐44. doi: 10.1016/j.phymed.2010.08.014. Epub 2010 Oct 30.

105 Boon-‐Niermeijer EK, van den Berg A, Wikman G, Wiegant FA. Phyto-‐adaptogens protect against environmental stress-‐induced death of embryos from the freshwater snail Lymnaea stagnalis. Phytomedicine 2000;7:389-‐399.

106 Edwards D, Heufelder A, Zimmermann A. Therapeutic effects and safety of Rhodiola rosea extract WS® 1375 in subjects with life-‐stress symptoms-‐-‐results of an open-‐label study. Phytother Res. 2012 Aug;26(8):1220-‐5. doi: 10.1002/ptr.3712. Epub 2012 Jan 6.

107 Stancheva SL, Mosharrof A. Effect of the extract of Rhodiola rosea L. on the content of the brain biogenic monamines. Med Physiol 1987;40:85-‐87.

108 Darbinyan V, Aslanyan G, Amroyan E, Gabrielyan E, Malmström C, Panossian A. Clinical trial of Rhodiola rosea L. extract SHR-‐5 in the treatment of mild to moderate depression. Nord J Psychiatry. 2007;61(5):343-‐8.

109 Petkov VD, Yonkov D, Mosharoff A, et al. Effects of alcohol aqueous extract from Rhodiola rosea L. roots on learning and memory. Acta Physiol Pharmacol Bulg 1986;12:3-‐16.

110 Vladeva SV1, Terzieva DD, Arabadjiiska DT. Effect of chromium on the insulin resistance in patients with type II diabetes mellitus. Folia Med (Plovdiv). 2005 ;47(3-‐4):59-‐62.

111 Lukaski, H. C., Bolonchuk, W. W., Siders, W. A. & Milne, D. B. (I 996). Chromium Supplementation and resistance training: effects on body composition, strength, and trace elements of men-‐ American Joumal of Clinical Nutrition, 6, 954-‐965.

112 Docherty JP, Sack DA, Roffman M, Finch M, Komorowski JR. A double-‐blind, placebo-‐ controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving. J Psychiatr Pract. 2005 Sep;11(5):302-‐14.

MedActiv™ Monograph References Only · Distributed!exclusively!by:!!!!!...

Documents

Transcript of MedActiv™ Monograph References Only · Distributed!exclusively!by:!!!!!...